Zamira Life Sciences was established in 2008 and is jointly owned by Australian and Korean investors.

Zamira markets research-based products for improved health, well-being and productivity in food-producing animals. Through the experience and capabilities of its shareholders, Zamira has the ability to rapidly develop new products which meet changing and emerging market needs.

Zamira’s Korean partner is CTCBio Inc (http://ctcbio.com/eng/), a publicly listed company on the Korean Secondary Market (KOSDAQ). CTCBio has R&D and manufacturing capabilities meeting pharmaceutical GMP standards.  Zamira Australia’s management team have many years of combined experience in the global animal health and biotechnology industries.

Vision

The vision for Zamira is to establish a substantial, marketing-driven global veterinary pharmaceuticals company.

Zamira will achieve growth by offering high quality, affordable, branded products that meet real needs of customers.

Zamira will be more successful than its competitors by bringing new products to market quickly and by rapidly adapting to changes in market conditions.

New Product Pipeline

Zamira has access to the product pipeline evolving from the CTCBio technology platform (http://ctcbio.com/eng/).

By drawing on the CTCBio technology platform Zamira is capable of rapidly developing a wide range of new products to meet changing and emerging market needs.

This platform is developed around 3 core capabilities:

1. Drug Delivery System (DDS)

CTCBio’s patented Drug Delivery System (DDS) involves a unique microencapsulation and granulation technique for powdered products.

DDS enables more potent drug delivery and more flexibility in relation to drug applications by offering capabilities including combination of multi-actives and coatings with pH adjustable and hydrophobic properties. DDS also provides effective flavour masking of bitter compounds to improve intake of medicated and other feeds.

Using this technology Zamira can therefore supply products with improved efficacy to address specific needs of customers.

2. Plant Extracts

CTCBio have analysed and assessed a vast range of naturally occurring plant extracts in vitro and in vivo across a range of animal species. The library of derived active compounds is accessed by CTCBio for the development of new non-medicated solutions to health and productivity issues.

3. Fermentation

Over many years, CTCBio’s qualified fermentation scientists have developed core capabilities in the application of fermentation techniques for generating cost effective active ingredients.